Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times

35
9
Favorite

Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times

Dow Jones2021-06-11

Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（9）

Wayne77
·2021-06-11
???
Reply
Like
Report
Clarity
·2021-06-11
[Miser] [Miser] [Miser]
Reply
Like
Report
Yellen
·2021-06-11
Help me like tks
Reply
4
Report
WilsonTan112
·2021-06-11
Response
Reply
2
Report
Fold Replies
- Yappyyell:
  [What]
  2021-06-11
  Reply
  Report
irung
·2021-06-11
Comment pls
Reply
5
Report
Fold Replies
- Veldin:
  Up
  2021-06-11
  Reply
  Report
irung
·2021-06-11
Like pls
Reply
5
Report
Fold Replies
- JunJie:
  cool
  2021-06-11
  Reply
  Report
deadcow
·2021-06-11
up up
Reply
5
Report
Fold Replies
- VeldinReplying tobeebeeyan:
  Up
  2021-06-11
  Reply
  Report
- deadcow:
  naik
  2021-06-11
  Reply
  Report
- beebeeyan:
  up up
  2021-06-11
  Reply
  Report
View more 2 comments
TCRaN
·2021-06-11
Like
Reply
5
Report
Fold Replies
- Veldin:
  Up
  2021-06-11
  Reply
  Report
- jerminos:
  Done! Help comment. thanks!
  2021-06-11
  Reply
  Report
Roticanai
·2021-06-11
Like
Reply
2
Report
Fold Replies
- TCRaN:
  like
  2021-06-11
  Reply
  Report
- SfunReplying todeadcow:
  up up up
  2021-06-11
  Reply
  Report
- deadcow:
  up up
  2021-06-11
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2142163227?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-11 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2142163227","market":"us","top_or_hot":-1,"title":"Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times","media":"Dow Jones","content":"<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times\n</h2>\n\n<h4 class=\"meta\">\n\n2021-06-11 10:05 北京时间&nbsp;&nbsp;&nbsp;<strong>Dow Jones</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLTO","symbol_name":"Galecto Inc.","start_time":0,"source_url":null,"article_id":"2142163227","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2142163227","pubTimestamp":1623377100,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharma","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLTO":"Galecto Inc."},"translate_title":"Orphazyme公司股价飙升导致20次波动性停摆，Galecto公司股价停摆7次","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLTO":0.9,"ORPH":0.9},"content_text":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":181256750,"gmtCreate":1623398321470,"gmtModify":1704202520757,"author":{"id":"3573033041140696","authorId":"3573033041140696","authorIdStr":"3573033041140696","name":"Wayne77","avatar":"https://static.tigerbbs.com/67d3224987d29dfccad80b3fe4074912","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573033041140696"},"htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181256750","repostId":2142163227,"repostType":2,"repost":{"id":"2142163227","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623377100,"share":"https://ttm.financial/m/news/2142163227?lang=&edition=fundamental","pubTime":"2021-06-11 10:05","market":"us","language":"en","title":"Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2142163227","media":"Dow Jones","summary":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharma","content":"<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-11 10:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLTO":"Galecto Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142163227","content_text":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181222347,"gmtCreate":1623397674489,"gmtModify":1704202507764,"author":{"id":"3562662036291129","authorId":"3562662036291129","authorIdStr":"3562662036291129","name":"Clarity","avatar":"https://static.tigerbbs.com/290bda4a10a88bafe28971dd816e57cc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3562662036291129"},"htmlText":"[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","text":"[Miser] [Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181222347","repostId":2142163227,"repostType":4,"repost":{"id":"2142163227","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623377100,"share":"https://ttm.financial/m/news/2142163227?lang=&edition=fundamental","pubTime":"2021-06-11 10:05","market":"us","language":"en","title":"Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2142163227","media":"Dow Jones","summary":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharma","content":"<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-11 10:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLTO":"Galecto Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142163227","content_text":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181178154,"gmtCreate":1623381455278,"gmtModify":1704202134136,"author":{"id":"3570181867008704","authorId":"3570181867008704","authorIdStr":"3570181867008704","name":"Yellen","avatar":"https://static.tigerbbs.com/4a94cccd5a8eeddae49b5113dd392f79","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570181867008704"},"htmlText":"Help me like tks","listText":"Help me like tks","text":"Help me like tks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181178154","repostId":2142163227,"repostType":4,"repost":{"id":"2142163227","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623377100,"share":"https://ttm.financial/m/news/2142163227?lang=&edition=fundamental","pubTime":"2021-06-11 10:05","market":"us","language":"en","title":"Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2142163227","media":"Dow Jones","summary":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharma","content":"<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-11 10:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLTO":"Galecto Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142163227","content_text":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181141468,"gmtCreate":1623380795454,"gmtModify":1704202118188,"author":{"id":"3576822898262586","authorId":"3576822898262586","authorIdStr":"3576822898262586","name":"WilsonTan112","avatar":"https://static.tigerbbs.com/49d6c7786d8d875e327f815c2f6be2f9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3576822898262586"},"htmlText":"Response&nbsp;","listText":"Response&nbsp;","text":"Response","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181141468","repostId":2142163227,"repostType":4,"repost":{"id":"2142163227","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623377100,"share":"https://ttm.financial/m/news/2142163227?lang=&edition=fundamental","pubTime":"2021-06-11 10:05","market":"us","language":"en","title":"Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2142163227","media":"Dow Jones","summary":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharma","content":"<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-11 10:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLTO":"Galecto Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142163227","content_text":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4680958,"gmtCreate":1623392518274,"gmtModify":1663228438732,"authorId":3582712915585862,"author":{"id":3582712915585862,"authorId":3582712915585862,"name":"Yappyyell","avatar":"https://static.tigerbbs.com/9e2de602327fd6668cd4baeadff7e967","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181141468,"type":1,"supId":0,"prevId":0,"content":"[What]","text":"[What]","html":"[What]"}],"langContent":"EN"},{"id":181184501,"gmtCreate":1623378778303,"gmtModify":1704202069996,"author":{"id":"3583644447757935","authorId":"3583644447757935","authorIdStr":"3583644447757935","name":"irung","avatar":"https://static.tigerbbs.com/1385729dc91be2a1cd7a1b5e5783dca3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583644447757935"},"htmlText":"Comment pls","listText":"Comment pls","text":"Comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181184501","repostId":2142163227,"repostType":4,"repost":{"id":"2142163227","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623377100,"share":"https://ttm.financial/m/news/2142163227?lang=&edition=fundamental","pubTime":"2021-06-11 10:05","market":"us","language":"en","title":"Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2142163227","media":"Dow Jones","summary":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharma","content":"<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-11 10:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLTO":"Galecto Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142163227","content_text":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4677932,"gmtCreate":1623379372332,"gmtModify":1663228422645,"authorId":3581838843201713,"author":{"id":3581838843201713,"authorId":3581838843201713,"name":"Veldin","avatar":"https://static.tigerbbs.com/1066c001ce0c01a3b97656619c989986","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.53%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181184501,"type":1,"supId":0,"prevId":0,"content":"Up","text":"Up","html":"Up"}],"langContent":"EN"},{"id":181182573,"gmtCreate":1623378683492,"gmtModify":1704202067027,"author":{"id":"3583644447757935","authorId":"3583644447757935","authorIdStr":"3583644447757935","name":"irung","avatar":"https://static.tigerbbs.com/1385729dc91be2a1cd7a1b5e5783dca3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583644447757935"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181182573","repostId":2142163227,"repostType":4,"repost":{"id":"2142163227","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623377100,"share":"https://ttm.financial/m/news/2142163227?lang=&edition=fundamental","pubTime":"2021-06-11 10:05","market":"us","language":"en","title":"Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2142163227","media":"Dow Jones","summary":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharma","content":"<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-11 10:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLTO":"Galecto Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142163227","content_text":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4683783,"gmtCreate":1623403210484,"gmtModify":1663228451634,"authorId":3554034677029324,"author":{"id":3554034677029324,"authorId":3554034677029324,"name":"JunJie","avatar":"https://static.tigerbbs.com/f716c717e7ddcae5f5912cad93972634","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.36%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181182573,"type":1,"supId":0,"prevId":0,"content":"<u>cool</u>","text":"<u>cool</u>","html":"<u>cool</u>"}],"langContent":"EN"},{"id":181136529,"gmtCreate":1623377609761,"gmtModify":1704202037391,"author":{"id":"3579085067033099","authorId":"3579085067033099","authorIdStr":"3579085067033099","name":"deadcow","avatar":"https://static.tigerbbs.com/b73e551a33ab83c745d06a9d890b1f93","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579085067033099"},"htmlText":"up up","listText":"up up","text":"up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/181136529","repostId":2142163227,"repostType":4,"repost":{"id":"2142163227","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623377100,"share":"https://ttm.financial/m/news/2142163227?lang=&edition=fundamental","pubTime":"2021-06-11 10:05","market":"us","language":"en","title":"Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2142163227","media":"Dow Jones","summary":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharma","content":"<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-11 10:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLTO":"Galecto Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142163227","content_text":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4677927,"gmtCreate":1623379353727,"gmtModify":1663228424642,"authorId":3581838843201713,"author":{"id":3581838843201713,"authorId":3581838843201713,"name":"Veldin","avatar":"https://static.tigerbbs.com/1066c001ce0c01a3b97656619c989986","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.53%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3581331692871918,"repliedAuthor":{"id":3581331692871918,"authorId":3581331692871918,"name":"beebeeyan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":181136529,"type":1,"supId":4677440,"prevId":4677470,"content":"Up","text":"Up","html":"Up"},{"id":4677498,"gmtCreate":1623377873784,"gmtModify":1663228421547,"authorId":3579085067033099,"author":{"id":3579085067033099,"authorId":3579085067033099,"name":"deadcow","avatar":"https://static.tigerbbs.com/b73e551a33ab83c745d06a9d890b1f93","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181136529,"type":1,"supId":4677456,"prevId":0,"content":"nai<u><u>k</u></u>","text":"nai<u><u>k</u></u>","html":"nai<u><u>k</u></u>"},{"id":4677470,"gmtCreate":1623377708808,"gmtModify":1663228421246,"authorId":3581331692871918,"author":{"id":3581331692871918,"authorId":3581331692871918,"name":"beebeeyan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181136529,"type":1,"supId":4677440,"prevId":0,"content":"up u<u>p</u>","text":"up u<u>p</u>","html":"up u<u>p</u>"},{"id":4677456,"gmtCreate":1623377663090,"gmtModify":1663228420930,"authorId":3579425512905776,"author":{"id":3579425512905776,"authorId":3579425512905776,"name":"Sfun","avatar":"https://static.tigerbbs.com/677878018d08b9f3288b2153431bff4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181136529,"type":1,"supId":0,"prevId":0,"content":"up up","text":"up up","html":"up up"},{"id":4677440,"gmtCreate":1623377626028,"gmtModify":1663228420337,"authorId":3579085067033099,"author":{"id":3579085067033099,"authorId":3579085067033099,"name":"deadcow","avatar":"https://static.tigerbbs.com/b73e551a33ab83c745d06a9d890b1f93","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181136529,"type":1,"supId":0,"prevId":0,"content":"up up","text":"up up","html":"up up"}],"langContent":"EN"},{"id":181139719,"gmtCreate":1623377387431,"gmtModify":1704202033126,"author":{"id":"3581772577454351","authorId":"3581772577454351","authorIdStr":"3581772577454351","name":"TCRaN","avatar":"https://static.tigerbbs.com/60cd232b0f9d8e680c9d686852e39bcb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581772577454351"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/181139719","repostId":2142163227,"repostType":4,"repost":{"id":"2142163227","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623377100,"share":"https://ttm.financial/m/news/2142163227?lang=&edition=fundamental","pubTime":"2021-06-11 10:05","market":"us","language":"en","title":"Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2142163227","media":"Dow Jones","summary":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharma","content":"<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-11 10:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLTO":"Galecto Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142163227","content_text":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4677923,"gmtCreate":1623379333422,"gmtModify":1663228423839,"authorId":3581838843201713,"author":{"id":3581838843201713,"authorId":3581838843201713,"name":"Veldin","avatar":"https://static.tigerbbs.com/1066c001ce0c01a3b97656619c989986","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.53%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181139719,"type":1,"supId":0,"prevId":0,"content":"Up","text":"Up","html":"Up"},{"id":4677366,"gmtCreate":1623377410261,"gmtModify":1663228420842,"authorId":3583841475339760,"author":{"id":3583841475339760,"authorId":3583841475339760,"name":"jerminos","avatar":"https://static.tigerbbs.com/4b6b79d65a5ecd18fecf889c39f99b14","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181139719,"type":1,"supId":0,"prevId":0,"content":"Done! Help comment. thanks!","text":"Done! Help comment. thanks!","html":"Done! Help comment. thanks!"}],"langContent":"EN"},{"id":181197363,"gmtCreate":1623377282852,"gmtModify":1704202029495,"author":{"id":"3581913988119713","authorId":"3581913988119713","authorIdStr":"3581913988119713","name":"Roticanai","avatar":"https://static.tigerbbs.com/4da10b7952b9a699e2c4703a67642740","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581913988119713"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/181197363","repostId":2142163227,"repostType":4,"repost":{"id":"2142163227","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623377100,"share":"https://ttm.financial/m/news/2142163227?lang=&edition=fundamental","pubTime":"2021-06-11 10:05","market":"us","language":"en","title":"Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2142163227","media":"Dow Jones","summary":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharma","content":"<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme stock's rocket ride leads to 20 volatility halts, Galecto stock halted 7 times\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-11 10:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <a href=\"https://laohu8.com/S/ORPH\">Orphazyme A/S</a> (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech <a href=\"https://laohu8.com/S/GLTO\">Galecto Inc.</a>'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&amp;P 500 rose 0.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLTO":"Galecto Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142163227","content_text":"Shares of Orphazyme A/S (ORPHA.KO) blasted 383.8% higher, enough to make the Denmark-based biopharmaceutical company's stock by far the biggest gainer listed on major U.S. exchanges, prior to a trading halt. The stock, which was up as much as 1,387% at its intraday high of $77.77, was halted for volatility for the 20th time Thursday at 3:24 p.m. Eastern with the last trade at $25.30, and remains halted. The stock's rally gave the company a market capitalization of $884.3 million. The company confirmed that there was no news released Thursday. The last announcement was May 7, when the company said a pivotal trial of its treatment for Lou Gehrig's disease failed to meet primary and secondary endpoints, sending the stock plunging 32.8% that day. After Orphazyme, the next biggest gainer Thursday was Boston-based biotech Galecto Inc.'s stock (GLTO), which ran up 170.0% prior to its seventh halt for volatility at 3:15 p.m. The stock's rallies comes as Nasdaq Composite gained 0.8% and the S&P 500 rose 0.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4677354,"gmtCreate":1623377374158,"gmtModify":1663228422032,"authorId":3581772577454351,"author":{"id":3581772577454351,"authorId":3581772577454351,"name":"TCRaN","avatar":"https://static.tigerbbs.com/60cd232b0f9d8e680c9d686852e39bcb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181197363,"type":1,"supId":0,"prevId":0,"content":"<u>like</u>","text":"<u>like</u>","html":"<u>like</u>"},{"id":4677451,"gmtCreate":1623377651932,"gmtModify":1663228420631,"authorId":3579425512905776,"author":{"id":3579425512905776,"authorId":3579425512905776,"name":"Sfun","avatar":"https://static.tigerbbs.com/677878018d08b9f3288b2153431bff4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3579085067033099,"repliedAuthor":{"id":3579085067033099,"authorId":3579085067033099,"name":"deadcow","avatar":"https://static.tigerbbs.com/b73e551a33ab83c745d06a9d890b1f93","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":181197363,"type":1,"supId":4677354,"prevId":4677436,"content":"up up u<u>p</u>","text":"up up u<u>p</u>","html":"up up u<u>p</u>"},{"id":4677436,"gmtCreate":1623377620073,"gmtModify":1663228420338,"authorId":3579085067033099,"author":{"id":3579085067033099,"authorId":3579085067033099,"name":"deadcow","avatar":"https://static.tigerbbs.com/b73e551a33ab83c745d06a9d890b1f93","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181197363,"type":1,"supId":4677354,"prevId":0,"content":"up up","text":"up up","html":"up up"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":35,"commentSize":9,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}